This article first appeared on GuruFocus.
AstraZeneca (NYSE:AZN), the global pharmaceutical and oncology company, traded at $164.75 Thursday as positive Tezspire data failed to shake investors out of their defensive crouch. Its London-listed shares fell roughly 0.6%, remaining 14% below their level before Wainua’s surprise trial failure in July. The message was blunt: one clinical win does not erase a major pipeline scar.
The Phase 3 CROSSING study delivered across the board. Both Tezspire doses significantly reduced tissue inflammation and eased swallowing problems in adults and adolescents with eosinophilic esophagitis. The improvements appeared by week 24, lasted through week 52 and came with a safety profile broadly consistent with the drug’s approved uses.
AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success ยท us.finance.gurufocus
Tezspire produced $1.13 billion of AstraZeneca’s 2025 sales and $1.48 billion for partner Amgen, so another indication could add meaningful fuel. But it still represents only about 1.4% of AstraZeneca’s $80 billion revenue target for 2030. At $164.75, the shares sit 9.25% below their $181.55 GF Value estimate. That discount looks tempting, but the market wants more than one good readoutit wants proof that AstraZeneca’s wider pipeline can fire again.